SecBot SecBot
Biotech Drug Report Generated Jul 6, 2026

Evkeeza

REGN·REGENERON PHARMACEUTICALS, INC.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already approved and commercialized since February 2021 (US) and June 2021 (EU). Latest label expansion (ages 1-5) approved September 2025.
Why 4/10
Evkeeza is already FDA- and EMA-approved and actively marketed; the most recent hard catalyst, the label expansion to children aged 1 to less than 5 years, occurred on September 26, 2025. No new PDUFA or pivotal readout is scheduled in the next ~12 months, and the drug is a small (<~1% of revenue) contributor to Regeneron's $14.3B top line, capping share-price impact potential.
Actionable Insight NEUTRAL

Evkeeza is a first-in-class ANGPTL3 inhibitor approved for an ultra-rare cholesterol disorder (HoFH, ~1,300 US patients). It is already de-risked by FDA approval but contributes only ~$130-150M in annual US sales versus Regeneron's ~$14.3B total revenue. The stock is primarily driven by Dupixent, EYLEA, and the broader pipeline, not this one drug. Watch quarterly Evkeeza US sales for gradual label-expansion uptake, but do not expect binary swings from this asset.

Price Chart

Loading chart...

Executive Summary

Evkeeza (evinacumab) is Regeneron's first-in-class ANGPTL3-inhibitor antibody for homozygous familial hypercholesterolemia (HoFH), an ultra-rare genetic condition affecting roughly 1,300 people in the US. FDA-approved since February 2021, its label has progressively expanded to cover all children down to age 1 as of September 2025. The drug is priced at ~$450,000/year list price and generated around $72.1M in US sales in H1 2025. While a meaningful option for a small patient population, Evkeeza is a minor contributor (~1%) to Regeneron's ~$14.3B in annual revenue, and the stock is overwhelmingly driven by larger franchises (Dupixent, EYLEA, Libtayo) and pipeline candidates.

How It Works

Evkeeza is a lab-engineered antibody (a type of protein) that is given as a monthly IV infusion. It works by blocking a protein called ANGPTL3, which normally interferes with the body's ability to break down fats and cholesterol. By blocking ANGPTL3, the drug helps clear "bad" LDL cholesterol from the bloodstream. This is a different mechanism from statins or PCSK9 inhibitors (like Repatha or Leqvio).

Trial Status

Evkeeza gained initial FDA approval in February 2021 for patients aged 12+ with HoFH based on the pivotal Phase 3 ELIPSE HoFH trial, which showed adding evinacumab to standard lipid-lowering therapies reduced LDL-C by ~50% at 24 weeks versus placebo. The label was expanded to children aged 5-11 in 2023 (single-arm open-label trial), and further expanded to children aged 1 to less than 5 in September 2025.

The Two-Sided Case

▲ Bull Case5
First-in-class ANGPTL3 inhibitor with a differentiated mechanism from statins and PCSK9 inhibitors, no direct HoFH competitor with the same mechanism.
Progressive label expansion (12+ in 2021, 5-11 in 2023, 1-5 in Sept 2025) steadily broadens the addressable patient pool within the ~1,300 US HoFH population.
Pivotal Phase 3 data showed ~50% LDL-C reduction when added to standard therapy, a clinically meaningful efficacy signal in a high-unmet-need population.
Ultragenyx partnership (Jan 2022) handles ex-US commercialization, allowing Regeneron to access global rare-disease infrastructure without major investment.
High list price (~$450K/year) means even a small absolute patient count can generate a $100M+ annual revenue stream.
▼ Bear Case5
Ultra-rare indication (~1,300 US patients) inherently limits peak sales potential; even full penetration caps revenue at a few hundred million dollars annually.
Evkeeza contributed only ~$72.1M in US sales in H1 2025, roughly 1% of Regeneron's ~$14.3B total FY2025 revenue, making it essentially immaterial to the stock's direction.
The list price of ~$450K/year faces payer pushback; Canadian HTA analysis estimated a ~98% price reduction would be needed for cost-effectiveness at $50K/QALY.
Potential future competition from other HoFH therapies or ANGPTL3-targeting approaches could limit share, though none are currently approved.
IV infusion burden (monthly, in-clinic) limits convenience versus subcutaneous self-injected alternatives (PCSK9 inhibitors), though these target a different mechanism.

Upcoming Catalysts

  • Quarterly earnings reports showing Evkeeza US sales growth from the label expansion to ages 1-5
  • Potential label expansion into broader hypercholesterolemia or severe hypertriglyceridemia (early-stage exploration)
  • Ex-US commercialization ramp by Ultragenyx, periodic updates on European/ROW launches and reimbursement

Source Filing

The SecBot filing or press-release report that triggered this drug report:

REGENERON PHARMACEUTICALS, INC. 8-K REGN ·Originating report

Sources · 12

Hover a chip for the title
1 drugs.com2 fda.gov3 aspconline.org4 biospace.com5 fiercepharma.com6 finviz.com7 fiercepharma.com8 tctmd.com9 uspharmacist.com10 investor.regeneron.com11 drugpatentwatch.com12 en.wikipedia.org